The Bull Rankings scorecard — our quality-growth score is 75.8 / 100, built from three pillars scored 0–100: Quality 60, Growth 85, Value 85 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 11% next year, then recovering toward 4% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Cigna Group’s stock is trading at a price that already discounts the business’s recent performance. The Bull Rankings model gives CI a 75.8/100 quality‑growth score, with Growth 85 as the strongest pillar and Quality 60 as the softest. The high Growth score reflects a 11.3 % year‑over‑year revenue increase and a 16.8 % ROE, while the moderate Quality score signals that margins and capital efficiency are solid but not spectacular.
The price, at $270.53 against a trailing‑12‑month P/E of 11.2, sits on the cheap side of the sector, with a PEG of 0.73. In other words, the market is already betting that the business will slow. If the company can keep accelerating revenue while maintaining its modest profit margin, the stock is undervalued.
What the business actually is
Cigna’s revenue engine is split into two segments. Evernorth Health Services delivers pharmacy benefit management, specialty pharmacy, and clinical programs that drive whole‑person health outcomes. Cigna Healthcare offers U.S. health insurance plans to individuals, employers, and Medicare Advantage customers. The specialty pharmacy and pharmacy benefit services within Evernorth are the primary growth drivers, as they capture higher‑margin, high‑volume drug distribution and benefit design consulting.
Why it can (or can't) keep compounding
The company’s 16.8 % ROE shows it turns equity into profit efficiently, while a debt‑to‑equity of 0.74 keeps leverage manageable. The low beta of 0.32 indicates that the business is less volatile than the market, a sign of steady cash flows. The 2.3 % profit margin, though modest, is supported by the scale of its pharmacy network and the pricing power of its benefit‑management contracts.
Evernorth’s specialty pharmacy and pharmacy benefit management are difficult to replicate quickly. They require deep data analytics, long‑term provider relationships, and regulatory expertise. Competitors would need to build comparable networks and negotiate similar benefit‑design contracts, a process that takes years. This moat, combined with the company’s ability to generate free cash flow of $9.1 b, underpins the model’s Growth pillar.
The valuation question
The market’s implied free‑cash‑flow growth of ‑11 % in the first year is a clear sign of pessimism. It is lower than the 11.3 % revenue growth reported for FY 2026, meaning the price already assumes the business will slow. The P/E of 11.2 and PEG of 0.73 place CI on the cheap side of its peers, yet the reverse‑DCF suggests the market is waiting for a slowdown. If revenue growth stays near double digits and free cash flow expands, the current price is a bargain. Conversely, if the company’s growth stalls, the price may already be over‑valued.
The bear case
The softest pillar in the model is Quality, scoring 60. That signals that while the company is profitable, its margins are thin and could erode if drug pricing pressures intensify or if payer contracts tighten. A decline in the 2.3 % profit margin would hurt free cash flow and could force the company to cut dividends or buybacks, which would dampen investor enthusiasm.
What would change our mind
- Profit margin falling below 2 % would confirm the Quality pillar’s weakness and suggest pricing power is eroding.
- Revenue growth slipping below 8 % would undermine the Growth pillar and push the reverse‑DCF implied growth above the actual growth, turning the price into a premium.
- Debt‑to‑equity rising above 1.0 would signal higher leverage risk, eroding the company’s capital efficiency and pushing the Quality score lower.
If any of these thresholds are breached, the thesis would shift from a value play to a cautionary stance.